Amneal Pharmaceuticals (AMRX) Long-Term Deferred Tax (2017 - 2019)

Amneal Pharmaceuticals' Long-Term Deferred Tax history runs 3 years deep, the most recent figure standing at $391.9 million for Q2 2019.

• In Q2 2019, Long-Term Deferred Tax rose 4.86% year-over-year to $391.9 million; the TTM figure through Jun 2019 stood at $391.9 million (up 4.86% YoY), while the FY2018 annual figure was $373.2 million, up 41454.45% from the prior year.
• Long-Term Deferred Tax for Q2 2019 stood at $391.9 million, up from $382.9 million in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $391.9 million in Q2 2019, with the low at $898000.0 in Q4 2017.
• The 3-year median for Long-Term Deferred Tax is $373.4 million (2018), against an average of $314.8 million.
• The sharpest annual moves came in 2018 and 2019: Long-Term Deferred Tax surged 41454.45% in 2018, then gained 4.86% in 2019.
• Amneal Pharmaceuticals' Long-Term Deferred Tax stood at $898000.0 in 2017, then soared by 41454.45% to $373.2 million in 2018, then rose by 5.02% to $391.9 million in 2019.
• Business Quant data shows AMRX's Long-Term Deferred Tax at $391.9 million in Q2 2019, $382.9 million in Q1 2019, and $373.2 million in Q4 2018.